A
What happened
Congress is revisiting the Trump administration's drug pricing plan, focusing on most-favored nation pricing. A closed-door meeting with Republican staffers and health policy experts explored aggressive measures to lower U.S. drug prices, reflecting a shift in Republican interest towards such policies.
★
Key insights
-
1
Growing Republican Interest: Republicans are increasingly considering aggressive drug pricing measures.
-
2
Most-Favored Nation Pricing: The proposed policy would align U.S. drug prices with those of other countries.
-
3
Closed-Door Discussions: Health policy experts and congressional staffers met to discuss drug pricing strategies.
Takeaways
The discussions indicate a potential shift in drug pricing policy among Republicans.